.
.
.
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial.
Mohan A, Tiwari P, Suri TM, Mittal S, Patel A, Jain A, Velpandian T, Das US, Boppana TK, Pandey RM, Shelke SS, Singh AR, Bhatnagar S, Masih S, Mahajan S, Dwivedi T, Sahoo B, Pandit A, Bhopale S, Vig S, Gupta R, Madan K, Hadda V, Gupta N, Garg R, Meena VP, Guleria R.
. Shah ASV, et al. N Engl J Med. 2021 Sep 8:NEJMc2106757. doi: 10.1056/NEJMc2106757. Online ahead of print. N Engl J Med. 2021. PMID: 34496200
.
Item in Clipboard
.
- Gluten intolerance a significant risk factor
- Infectious disease of the uterus
- Absence of an individual specific disease